163 related articles for article (PubMed ID: 16518605)
1. Optimal treatment intensity in children with Down syndrome and myeloid leukaemia: data from 56 children treated on NOPHO-AML protocols and a review of the literature.
Abildgaard L; Ellebaek E; Gustafsson G; Abrahamsson J; Hovi L; Jonmundsson G; Zeller B; Hasle H
Ann Hematol; 2006 May; 85(5):275-80. PubMed ID: 16518605
[TBL] [Abstract][Full Text] [Related]
2. Increased age at diagnosis has a significantly negative effect on outcome in children with Down syndrome and acute myeloid leukemia: a report from the Children's Cancer Group Study 2891.
Gamis AS; Woods WG; Alonzo TA; Buxton A; Lange B; Barnard DR; Gold S; Smith FO;
J Clin Oncol; 2003 Sep; 21(18):3415-22. PubMed ID: 12885836
[TBL] [Abstract][Full Text] [Related]
3. Acute leukaemia in children with Down syndrome: a population-based Nordic study.
Zeller B; Gustafsson G; Forestier E; Abrahamsson J; Clausen N; Heldrup J; Hovi L; Jonmundsson G; Lie SO; Glomstein A; Hasle H;
Br J Haematol; 2005 Mar; 128(6):797-804. PubMed ID: 15755283
[TBL] [Abstract][Full Text] [Related]
4. Repetitive cycles of high-dose cytarabine are effective for childhood acute myeloid leukemia: long-term outcome of the children with AML treated on two consecutive trials of Tokyo Children's Cancer Study Group.
Tomizawa D; Tabuchi K; Kinoshita A; Hanada R; Kigasawa H; Tsukimoto I; Tsuchida M;
Pediatr Blood Cancer; 2007 Aug; 49(2):127-32. PubMed ID: 16807916
[TBL] [Abstract][Full Text] [Related]
5. Treatment stratification based on initial in vivo response in acute myeloid leukaemia in children without Down's syndrome: results of NOPHO-AML trials.
Lie SO; Abrahamsson J; Clausen N; Forestier E; Hasle H; Hovi L; Jonmundsson G; Mellander L; Gustafsson G
Br J Haematol; 2003 Jul; 122(2):217-25. PubMed ID: 12846889
[TBL] [Abstract][Full Text] [Related]
6. Prospective study of a pirarubicin, intermediate-dose cytarabine, and etoposide regimen in children with Down syndrome and acute myeloid leukemia: the Japanese Childhood AML Cooperative Study Group.
Kudo K; Kojima S; Tabuchi K; Yabe H; Tawa A; Imaizumi M; Hanada R; Hamamoto K; Kobayashi R; Morimoto A; Nakayama H; Tsuchida M; Horibe K; Kigasawa H; Tsukimoto I;
J Clin Oncol; 2007 Dec; 25(34):5442-7. PubMed ID: 18048827
[TBL] [Abstract][Full Text] [Related]
7. Myeloid leukaemia in children with Down syndrome: report of the registry-based French experience between 1990 and 2003.
Tandonnet J; Clavel J; Baruchel A; Nacka F; Pérel Y
Pediatr Blood Cancer; 2010 Jul; 54(7):927-33. PubMed ID: 20405513
[TBL] [Abstract][Full Text] [Related]
8. Less toxicity by optimizing chemotherapy, but not by addition of granulocyte colony-stimulating factor in children and adolescents with acute myeloid leukemia: results of AML-BFM 98.
Creutzig U; Zimmermann M; Lehrnbecher T; Graf N; Hermann J; Niemeyer CM; Reiter A; Ritter J; Dworzak M; Stary J; Reinhardt D
J Clin Oncol; 2006 Sep; 24(27):4499-506. PubMed ID: 16983120
[TBL] [Abstract][Full Text] [Related]
9. AML patients with Down syndrome have a high cure rate with AML-BFM therapy with reduced dose intensity.
Creutzig U; Reinhardt D; Diekamp S; Dworzak M; Stary J; Zimmermann M
Leukemia; 2005 Aug; 19(8):1355-60. PubMed ID: 15920490
[TBL] [Abstract][Full Text] [Related]
10. Acute myeloid leukemia and Down syndrome evolution of modern therapy--state of the art review.
Gamis AS
Pediatr Blood Cancer; 2005 Jan; 44(1):13-20. PubMed ID: 15534881
[TBL] [Abstract][Full Text] [Related]
11. Optimizing therapy for myeloid disorders of Down syndrome.
Webb DK
Br J Haematol; 2005 Oct; 131(1):3-7. PubMed ID: 16173956
[TBL] [Abstract][Full Text] [Related]
12. [Improved results in the treatment of acute myeloid leukemia - Results of study AML-BFM-93 in East Germany with comparisons to the preceding studies AML-I-82 and AML-II-87].
Steinbach D; Dörffel W; Eggers G; Holfeld E; Kluba U; Krause I; Lauterbach I; Reiss T; Rieske K; Scharfe V; Schumacher R; Weigel H; Weinmann G; Zintl F; Hermann J
Klin Padiatr; 2001; 213(4):162-8. PubMed ID: 11528549
[TBL] [Abstract][Full Text] [Related]
13. Treating childhood acute myeloid leukaemia with the AML-BFM-83 protocol: experience in a developing country.
Chan LL; Abdel-Latif ME; Ariffin WA; Ariffin H; Lin HP
Br J Haematol; 2004 Sep; 126(6):799-805. PubMed ID: 15352983
[TBL] [Abstract][Full Text] [Related]
14. Continuous and high-dose cytarabine combined chemotherapy in children with down syndrome and acute myeloid leukemia: Report from the Japanese children's cancer and leukemia study group (JCCLSG) AML 9805 down study.
Taga T; Shimomura Y; Horikoshi Y; Ogawa A; Itoh M; Okada M; Ueyama J; Higa T; Watanabe A; Kanegane H; Iwai A; Saiwakawa Y; Kogawa K; Yamanaka J; Tsurusawa M
Pediatr Blood Cancer; 2011 Jul; 57(1):36-40. PubMed ID: 21557456
[TBL] [Abstract][Full Text] [Related]
15. Long-term results in children with AML: NOPHO-AML Study Group--report of three consecutive trials.
Lie SO; Abrahamsson J; Clausen N; Forestier E; Hasle H; Hovi L; Jonmundsson G; Mellander L; Siimes MA; Yssing M; Zeller B; Gustafsson G; ;
Leukemia; 2005 Dec; 19(12):2090-100. PubMed ID: 16304571
[TBL] [Abstract][Full Text] [Related]
16. Long-term results of an ultra low-dose cytarabine-based regimen for the treatment of acute megakaryoblastic leukaemia in children with Down syndrome.
Al-Ahmari A; Shah N; Sung L; Zipursky A; Hitzler J
Br J Haematol; 2006 Jun; 133(6):646-8. PubMed ID: 16704441
[TBL] [Abstract][Full Text] [Related]
17. A population-based study of 272 children with acute myeloid leukaemia treated on two consecutive protocols with different intensity: best outcome in girls, infants, and children with Down's syndrome. Nordic Society of Paediatric Haematology and Oncology (NOPHO).
Lie SO; Jonmundsson G; Mellander L; Siimes MA; Yssing M; Gustafsson G
Br J Haematol; 1996 Jul; 94(1):82-8. PubMed ID: 8757513
[TBL] [Abstract][Full Text] [Related]
18. Preserved High Probability of Overall Survival with Significant Reduction of Chemotherapy for Myeloid Leukemia in Down Syndrome: A Nationwide Prospective Study in Japan.
Taga T; Watanabe T; Tomizawa D; Kudo K; Terui K; Moritake H; Kinoshita A; Iwamoto S; Nakayama H; Takahashi H; Shimada A; Taki T; Toki T; Ito E; Goto H; Koh K; Saito AM; Horibe K; Nakahata T; Tawa A; Adachi S
Pediatr Blood Cancer; 2016 Feb; 63(2):248-54. PubMed ID: 26481183
[TBL] [Abstract][Full Text] [Related]
19. Treatment-related deaths in second complete remission in childhood acute myeloid leukaemia.
Molgaard-Hansen L; Möttönen M; Glosli H; Jónmundsson GK; Abrahamsson J; Hasle H;
Br J Haematol; 2011 Mar; 152(5):623-30. PubMed ID: 21241281
[TBL] [Abstract][Full Text] [Related]
20. Relapse, not regimen-related toxicity, was the major cause of treatment failure in 11 children with Down syndrome undergoing haematopoietic stem cell transplantation for acute leukaemia.
Meissner B; Borkhardt A; Dilloo D; Fuchs D; Friedrich W; Handgretinger R; Peters C; Schrauder A; Schuster FR; Vormoor J; Maecker B; Sykora KW; Zintl F; Welte K; Sauer M
Bone Marrow Transplant; 2007 Nov; 40(10):945-9. PubMed ID: 17768387
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]